Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer’s disease: a systematic review and meta-analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Compared of efficacy and safety of high-dose donepezil vs standard-dose donepezil among elderly patients with Alzheimer’s disease: a systematic review and meta-analysis
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume -, Issue -, Pages 1-9
Publisher
Informa UK Limited
Online
2022-01-09
DOI
10.1080/14740338.2022.2027905
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease
- (2020) Andrea Haake et al. Expert Opinion On Drug Safety
- Different Doses of Pharmacological Treatments for Mild to Moderate Alzheimer’s Disease: A Bayesian Network Meta-Analysis
- (2020) Tingting Zhang et al. Frontiers in Pharmacology
- Research on endophytic fungi for producing huperzine A on a large-scale
- (2020) Xiao Sang et al. CRITICAL REVIEWS IN MICROBIOLOGY
- Donepezil, a drug for Alzheimer’s disease, promotes oligodendrocyte generation and remyelination
- (2019) Xue Cui et al. ACTA PHARMACOLOGICA SINICA
- Safety and tolerability of donepezil 23 mg with or without intermediate dose titration in patients with Alzheimer’s disease taking donepezil 10 mg: a multicenter, randomized, open-label, parallel-design, three-arm, prospective trial
- (2019) Yun Jeong Hong et al. Alzheimers Research & Therapy
- Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease
- (2019) Dan-Dan Li et al. Frontiers in Neuroscience
- Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics
- (2019) Sneham Tiwari et al. International Journal of Nanomedicine
- The effects of acetylcholinesterase inhibitors on the heart in acute myocardial infarction and heart failure: From cells to patient reports
- (2019) Thawatchai Khuanjing et al. Acta Physiologica
- Efficacy and Safety of Cholinesterase Inhibitors for Mild Cognitive Impairment:A Systematic Review and Meta-Analysis
- (2019) Shinji Matsunaga et al. JOURNAL OF ALZHEIMERS DISEASE
- Donepezil Treatment in Patients With Depression and Cognitive Impairment on Stable Antidepressant Treatment: A Randomized Controlled Trial
- (2018) Davangere P. Devanand et al. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
- Electrocardiogram Changes of Donepezil Administration in Elderly Patients with Ischemic Heart Disease
- (2018) Deguo Wang et al. Cardiology Research and Practice
- A review of clinical treatment considerations of donepezil in severe Alzheimer's disease
- (2018) Aida Adlimoghaddam et al. CNS Neuroscience & Therapeutics
- Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer's Disease: A Systematic Review and Meta-Analysis
- (2018) Chen-Chen Tan et al. JOURNAL OF ALZHEIMERS DISEASE
- Donepezil decreases heart rate in elderly patients with Alzheimer’s disease
- (2018) Zhengping Pu et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial
- (2017) Noll L. Campbell et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Dementia prevention, intervention, and care
- (2017) Gill Livingston et al. LANCET
- Donepezil 23 mg in Asian patients with moderate-to-severe Alzheimer's disease
- (2016) S. -H. Han et al. ACTA NEUROLOGICA SCANDINAVICA
- Drug treatments in Alzheimers disease
- (2016) R. Briggs et al. CLINICAL MEDICINE
- Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies
- (2016) Jeffrey Cummings et al. CNS Neuroscience & Therapeutics
- Efficacy and Safety of Sustained Release Donepezil High Dose versus Immediate Release Donepezil Standard Dose in Japanese Patients with Severe Alzheimer’s Disease: A Randomized, Double-Blind Trial
- (2016) Akira Homma et al. JOURNAL OF ALZHEIMERS DISEASE
- Increased plasma donepezil concentration improves cognitive function in patients with dementia with Lewy bodies: An exploratory pharmacokinetic/pharmacodynamic analysis in a phase 3 randomized controlled trial
- (2016) Etsuro Mori et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease
- (2016) William James Deardorff et al. Drug Design Development and Therapy
- Donepezil across the spectrum of Alzheimer's disease: dose optimization and clinical relevance
- (2015) J.-H. Lee et al. ACTA NEUROLOGICA SCANDINAVICA
- Evaluation of an 8-item Severe Impairment Battery (SIB-8) vs. the full SIB in moderate to severe Alzheimer's disease patients participating in a donepezil study
- (2014) F. A. Schmitt et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- The effect of funding sources on donepezil randomised controlled trial outcome: a meta-analysis
- (2014) Lewis O J Killin et al. BMJ Open
- High-Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer's Disease: Drug Profile and Clinical Guidelines
- (2013) Jeffrey L. Cummings et al. CNS Neuroscience & Therapeutics
- Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity
- (2013) Steven Ferris et al. Alzheimers Research & Therapy
- Which Cholinesterase Inhibitor is the Safest for the Heart in Elderly Patients With Alzheimer’s Disease?
- (2012) Ahmet Turan Isik et al. American Journal of Alzheimers Disease and Other Dementias
- Efficacy and Safety of Donepezil 23 mg versus Donepezil 10 mg for Moderate-to-Severe Alzheimers Disease: A Subgroup Analysis in Patients Already Taking or Not Taking Concomitant Memantine
- (2012) Rachelle S. Doody et al. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
- Cardiac Safety of Donepezil in Elderly Patients with Alzheimer Disease
- (2012) Ahmet Turan Isik et al. INTERNAL MEDICINE
- Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease
- (2012) Robert Howard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease
- (2011) Martin Farlow et al. BMC Neurology
- Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease
- (2011) Steven H Ferris et al. Alzheimers Research & Therapy
- Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study
- (2010) Martin R. Farlow et al. CLINICAL THERAPEUTICS
- Safety and Tolerability of Donepezil at Doses up to 20 mg/day
- (2009) Rachelle S Doody et al. DRUGS & AGING
- Cholinesterase Inhibitors and Incidence of Bradycardia in Patients with Dementia in the Veterans Affairs New England Healthcare System
- (2009) Rohini K. Hernandez et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Cholinesterase Inhibitors and Hospitalization for Bradycardia: A Population-Based Study
- (2009) Laura Y. Park-Wyllie et al. PLOS MEDICINE
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started